Skip Navigation Links
Related Categories Post
Publish Date : Jul 17, 2017
Categories: Health or Healthcare
Name of Organization : Market Data Forecast
Contact Number : 1-888-702-9626
Email :
Description :
Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market is expected to reach USD 12.43 billion by 2020 from USD 8.08 billion in 2015, growing at a CAGR of 9.00% during the forecast period 2015-2020.

View Full Report @

Attention deficit hyperactivity disorder (ADHD), is one of the most common neurological/psychiatric disorders among children and adolescents. ADHD is commonly observed in children (above 12 years age) as compared to adolescents. ADHD is also described as hyperkinetic disorder/ attention deficit disorder or neuropsychiatric disorder. The exact cause for the ADHD is not clear but, expected to be resulted due to genetic factors and environmental influences. ADHD results in improper functioning of nervous system that led to attention deficit and hyperactivity/impulsiveness condition.

Download Free Sample Report @

Global attention deficit hyperactivity disorder (ADHD) therapeutics market is segmented based on medication, psychotherapy, and education or training. Medication involves stimulants and non-stimulants. Medication by stimulants comprises of amphetamines, methylphenidate, dextroamphetamine, and dexmethylphenidate, whereas medication by non-stimulants comprises of atomoxetine, bupropion, and guanfacine. Psychotherapy involves behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy. Education or training involves parent management training, social skills training, and school-based interventions.

Avail Discount @

ADHD is characterized by certain symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The symptoms of attention deficit hyperactivity disorder (ADHD) are controlled by different modalities such as medication (stimulants-amphetamines; non-stimulants-atomoxetine), psychotherapy (behavior therapy, cognitive behavioral therapy), and education/training (parent management training, family training).

Buy now Report @

On the basis of geographical region the global attention deficit hyperactivity disorder (ADHD) therapeutics market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America commanded the highest share of 36.0% of the global attention deficit hyperactivity disorder (ADHD) therapeutics market in 2015, whereas Asia-Pacific is estimated to grow at the highest CAGR of 12.30% during the forecast period 2015-2020.

The key players in global attention deficit hyperactivity disorder (ADHD) therapeutics market such as, Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.), and Curemark, LLC. (U.S.).

About Market Data Forecast:

The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering Global among other regions of the global market as well. For more info kindly visit,


Abhishek Shukla

Sales Manager (International Business Development)

Market Data Forecast

Direct Line: +1-888-702-9626

Mobile: +91 998 555 0206


Visit MarketDataForecast Blog @

View latest Press Releases of MDF @

comments powered by Disqus

About Us | Term & Conditions

All the Names, Logos and Trademarks are properties of their respective Owners. © 2013-2018 Dzone Technologies . All Rights Reserved.